Alan McCormick is a founding partner of the purpose-driven investment firm Legatum. Legatum were one of the earliest investors in NTDs starting programmes in 2006, in Rwanda and Burundi, by trialling the first mass drug administration, which ultimately treated over 9.7 million people in four years. Seeing that NTDs affected over one billion of the world’s population, Legatum established the END Fund in 2012 as an independent vehicle to bring together private donors to accomplish one big goal: to see an end to the most prevalent NTDs once and for all.
Legatum is a global investment partnership that invests its proprietary capital in private and listed businesses and focuses its other energies on surfacing ideas and supporting initiatives that enable people, communities and nations to prosper. Mr. McCormick sits on the firm’s investment committee and has been particularly engaged with the group’s social investment portfolio. Over the last two decades, Mr. McCormick and his Partners have founded several philanthropic funds tackling global challenges including Luminos Fund focussed on out of school children, the Freedom Fund targeting the end of slavery, and the forthcoming Resilio Fund which will transform humanitarian aid.
Mr. McCormick has been with Legatum since its founding in 2006. He was formerly part of Legatum’s predecessor, Sovereign Asset Management, and a member of its special situations team.